Andreas Struengmann's Biography

Andreas Struengmann is a renowned German billionaire and entrepreneur best known for co-founding Hexal AG, a leading generic drug manufacturer, alongside his twin brother Thomas. Born on February 19, 1950, Struengmann holds a degree from the University of Augsburg and has built a legacy in the pharmaceutical industry. His strategic acumen was pivotal in the rapid growth and eventual sale of Hexal AG to Novartis, marking a significant milestone in his career. Andreas is further recognized for his early and impactful investments in BioNTech, the biotech company that developed one of the first effective COVID-19 vaccines. With a current net worth estimated at $12.7 billion in 2024, Struengmann remains at the forefront of healthcare innovation, investing in biotechnology, life sciences, and healthcare startups. He is also known for his philanthropic work and support for medical research. Despite his immense wealth, Andreas Struengmann keeps a low public profile, preferring to influence global health from behind the scenes. His business achievements and commitment to advancing medical science have earned him numerous accolades and respect in the international business community. Struengmann continues to inspire as a visionary leader, paving the way for future breakthroughs in healthcare and entrepreneurship.